Cargando…

Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study

The phase III GALLIUM trial assessed the safety and efficacy of obinutuzumab-based versus rituximab-based immunochemotherapy in patients with previously untreated follicular lymphoma (FL) or marginal zone lymphoma (MZL). At the primary analysis, the trial met its primary end point, demonstrating imp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Townsend, William, Hiddemann, Wolfgang, Buske, Christian, Cartron, Guillaume, Cunningham, David, Dyer, Martin J.S., Gribben, John G., Phillips, Elizabeth H., Dreyling, Martin, Seymour, John F., Grigg, Andrew, Trotman, Judith, Lin, Tong-Yu, Hong, Xiao-Nan, Kingbiel, Dirk, Nielsen, Tina G., Knapp, Andrea, Herold, Michael, Marcus, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10317485/ https://www.ncbi.nlm.nih.gov/pubmed/37404773 http://dx.doi.org/10.1097/HS9.0000000000000919

Ejemplares similares

Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial
por: Herold, Michael, et al.
Publicado: (2022)

Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma
por: Grigg, Andrew, et al.
Publicado: (2017)

Efficacy, safety, and molecular response predictors of oral ixazomib and short-course rituximab in untreated iNHL
por: Graf, Solomon A., et al.
Publicado: (2022)

Correction Notice: Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial
Publicado: (2022)

Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first‐line immunochemotherapy
por: Jamois, Candice, et al.
Publicado: (2019)

Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
por: Garau, Martina, et al.
Publicado: (2017)

Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression
por: Seymour, John F., et al.
Publicado: (2019)

A comparison of the prognostic performance of the Lugano 2014 and RECIL 2017 response criteria in patients with NHL from the phase III GOYA and GALLIUM trials
por: Kostakoglu, Lale, et al.
Publicado: (2023)

Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma
por: Davies, Andrew, et al.
Publicado: (2020)

GALLIUM trial: the tortoise (rituximab) and the hare (obinutuzumab) race
por: García-Muñoz, Ricardo, et al.
Publicado: (2019)

Follicular Lymphoma Evaluation Index (FLEX): A new clinical prognostic model that is superior to existing risk scores for predicting progression‐free survival and early treatment failure after frontline immunochemotherapy
por: Mir, Farheen, et al.
Publicado: (2020)

SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma
por: Stathis, Anastasios, et al.
Publicado: (2022)

Safety and efficacy of atezolizumab with obinutuzumab and bendamustine in previously untreated follicular lymphoma
por: Younes, Anas, et al.
Publicado: (2022)

P1090: LONG TERM FOLLOW-UP OF UNTREATED/RELAPSING MCL PATIENTS WITH THE IBRUTINIB, OBINUTUZUMAB, AND VENETOCLAX COMBINATION.
por: Le Gouill, Steven, et al.
Publicado: (2023)

Profile of obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia
por: Hill, Brian T, et al.
Publicado: (2015)

Rituximab Maintenance Versus Observation After Immunochemotherapy (R-CHOP, R-MCP, and R-FCM) in Untreated Follicular Lymphoma Patients: A Randomized Trial of the Ostdeutsche Studiengruppe Hämatologie und Onkologie and the German Low-Grade Lymphoma Study Group
por: Hirt, Carsten, et al.
Publicado: (2021)

Cost-effectiveness of obinutuzumab versus rituximab biosimilars for previously untreated follicular lymphoma
por: Spencer, Scott J, et al.
Publicado: (2021)

Comparative structural analyses of the NHL domains from the human E3 ligase TRIM–NHL family
por: Chaikuad, Apirat, et al.
Publicado: (2022)

Obinutuzumab: A FDA approved monoclonal antibody in the treatment of untreated chronic lymphocytic leukemia
por: Sachdeva, Mamta, et al.
Publicado: (2015)

Efficacy and safety of obinutuzumab for the first-line treatment of follicular lymphoma: a subgroup analysis of Chinese patients enrolled in the phase III GALLIUM study
por: Hong, Xiaonan, et al.
Publicado: (2022)

P1080: ZANUBRUTINIB PLUS OBINUTUZUMAB VERSUS OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATED ANALYSIS OF THE ROSEWOOD STUDY
por: Trotman, Judith, et al.
Publicado: (2023)

Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study
por: Stilgenbauer, Stephan, et al.
Publicado: (2018)

First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial
por: Moreno, Carol, et al.
Publicado: (2022)

Biomarkers in NHL
por: Malek, Sami N.
Publicado: (2011)

Rituximab and obinutuzumab differentially hijack the B cell receptor and NOTCH1 signaling pathways
por: Edelmann, Jennifer, et al.
Publicado: (2021)

TRIM-NHL protein, NHL-2, modulates cell fate choices in the C. elegans germ line
por: Brenner, John L., et al.
Publicado: (2022)

Obinutuzumab-induced coagulopathy in chronic lymphocytic leukaemia with trisomy 12
por: Walter, H S, et al.
Publicado: (2016)

PB2273: EFFICACY OF OBINUTUZUMAB - BASED REGIMENS IN PATIENTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA: A RETROSPECTIVE OBSERVATIONAL SINGLE-CENTER STUDY
por: Ridova, Nevenka, et al.
Publicado: (2023)

S145: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY
por: Al-Sawaf, Othman, et al.
Publicado: (2023)

A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA
por: Sehn, Laurie H., et al.
Publicado: (2020)

Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study
por: Leblond, Véronique, et al.
Publicado: (2018)

Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study
por: Bosch, Francesc, et al.
Publicado: (2019)

Feasibility of Combining the Phosphatidylinositol 3-Kinase Inhibitor Copanlisib With Rituximab-Based Immunochemotherapy in Patients With Relapsed Indolent B-cell Lymphoma
por: Matasar, Matthew J., et al.
Publicado: (2021)

Stem cell hunt in NHL
por: Merkel, Olaf, et al.
Publicado: (2015)

NHL - Extranodal T-cell lymphoma
por: Devi, Seema, et al.
Publicado: (2015)

Exploring Potential Germline-Associated Roles of the TRIM-NHL Protein NHL-2 Through RNAi Screening
por: Davis, Gregory M., et al.
Publicado: (2017)

Current trends of anticancer immunochemotherapy
por: Vacchelli, Erika, et al.
Publicado: (2013)

MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial
por: Pott, Christiane, et al.
Publicado: (2019)

Non-Hodgkin Lymphoma (NHL) in Pakistan
por: Pervez, Shahid
Publicado: (2012)

Obinutuzumab Can Be Administered as a 90-minute Short Duration Infusion in Patients With Previously Untreated Follicular Lymphoma: GAZELLE End of Induction Analysis
por: Canales, Miguel A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_aqf0k03sndaqvuj6n9qa9oh9hg